Britain and America have announced a major bilateral deal that will preserve zero import taxes on UK drug exports entering the American market.
The Terms of the Pact
As part of the deal, the UK has agreed to increase spending on pharmaceuticals through the National Health Service (NHS). This commitment secures that duties on these crucial products will be held at zero for a timeframe of three years.
This agreement is in response to recent statements to significantly raise duties on branded drug products, with figures mentioned up to double the cost.
"This deal with the Britain strengthens the international landscape for innovative medicines and establishes long-overdue balance to American-British medicine commerce," a statement noted.
Commercial Importance
Pharmaceuticals are one of the the United Kingdom's largest goods shipped to the US, which is by far the largest buyer for leading UK drugmakers.
Statistics indicate that in the 12 months prior to the third quarter, the UK shipped drugs totaling £11.1bn to the US. This figure made up a significant portion of British export trade in that period.
"This guarantee safeguards jobs, stimulates capital expenditure and sets the stage for the UK to emerge as a international leader for medical research," a minister stated.
Key NHS Changes
The agreement includes several key pledges from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it deems new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to increase overall public funding on drugs from 0.3% of the national economy to 0.6% over the next decade.
- Payback Limit: The percentage manufacturers must return to the NHS to stay within budget will be capped at 15%. In the past, rebates exceeded 20%.
Recent Tensions
The pact takes place against a protracted tension between the pharmaceutical industry and the ministers over spending levels and regulatory access.
These tensions were heightened by claims that US consumers were paying significantly more for the identical medicines than consumers in the UK and Europe.
In recent months, several significant pharmaceutical investments in the UK have been halted or scrapped, while multi-billion-dollar investments have been directed toward American operations.
The Science Minister stated that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had declined as a share of its total funding over the previous ten-year period.
